Boehringer Ingelheim (“BI”) , together with Professor Qu Jieming’s team at Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, jointly launched the “China Bronchiectasis Care Action” during the China International Import Expo (CIIE). The initiative will conduct public education focusing on disease recognition, standardized diagnosis and treatment, and long‑term management, aiming to pool the strength of multiple parties to improve bronchiectasis disease management and help more patients achieve longer and higher‑quality healthy lives.
Program Milestone
| Item | Detail |
|---|---|
| Parties | Boehringer Ingelheim (BI) and Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (Prof. Qu Jieming’s team) |
| Initiative | “China Bronchiectasis Care Action” |
| Launch Venue | China International Import Expo (CIIE), Shanghai |
| Announcement Date | 8 Nov 2026 |
| Focus Areas | Disease recognition; standardized diagnosis and treatment; long‑term management |
| Format | Public and patient education; professional physician exchanges; online and offline activities |
| Financial Terms | Not disclosed |
Program Profile & Key Activities
- Public‑Facing Education: Leveraging their respective strengths, both parties will jointly promote public‑oriented disease education and health education activities, raising awareness of bronchiectasis recognition and management.
- Professional Exchange: The initiative will advance professional exchanges among physicians to support standardized diagnosis and treatment of bronchiectasis across clinical settings.
- Online and Offline Activities: The two parties plan to carry out online and offline disease education activities, using more vivid and diverse formats to help more members of the public understand bronchiectasis and disease management knowledge.
- Multi‑Stakeholder Approach: The Care Action aims to pool the strength of multiple parties – industry, academic medicine, and the public health community – to jointly improve disease management outcomes.
Disease Context – Bronchiectasis
- Definition: Bronchiectasis is a chronic respiratory condition characterized by permanent, abnormal widening of the bronchi, leading to persistent cough, sputum production, and recurrent respiratory infections.
- Under‑Recognition: The disease remains under‑diagnosed and under‑appreciated in public awareness relative to other chronic respiratory conditions such as asthma and COPD, motivating education‑focused initiatives.
- Long‑Term Management: Effective care depends on early recognition, standardized diagnosis – typically confirmed by high‑resolution CT – and sustained long‑term management to reduce exacerbations and preserve lung function.
Market Impact & Outlook
- China Respiratory Strategy: The launch at CIIE underscores Boehringer Ingelheim’s continued commitment to China’s respiratory health agenda, complementing its pharmaceutical portfolio with disease‑awareness and care‑standardization programs.
- Academic–Industry Collaboration: Partnering with Ruijin Hospital – a leading academic medical center – anchors the initiative in clinical expertise and supports the diffusion of standardized care practices nationwide.
- Ecosystem Building: Public education combined with physician‑focused professional exchange addresses both demand‑side awareness and supply‑side care quality, a dual approach aimed at improving long‑term patient outcomes.
- Financial Impact: No immediate revenue contribution was disclosed; the Care Action is a disease‑management and public‑education initiative.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the implementation of the “China Bronchiectasis Care Action,” including planned public education activities, professional exchanges, and online and offline programs. Actual results may differ due to risks including program execution, stakeholder participation, healthcare policy developments, and the pace of adoption of standardized diagnosis and treatment practices.-Fineline Info & Tech
